These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26362197)

  • 1. Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.
    Rubio-Briones J; Borque A; Esteban LM; Casanova J; Fernandez-Serra A; Rubio L; Casanova-Salas I; Sanz G; Domínguez-Escrig J; Collado A; Gómez-Ferrer A; Iborra I; Ramírez-Backhaus M; Martínez F; Calatrava A; Lopez-Guerrero JA
    BMC Cancer; 2015 Sep; 15():633. PubMed ID: 26362197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
    Hansen J; Auprich M; Ahyai SA; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Fisch M; Abbou CC; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Pummer K; Graefen M; Haese A; Walz J; Briganti A; Shariat SF; Chun FK
    Eur Urol; 2013 Feb; 63(2):201-9. PubMed ID: 22854248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
    Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
    Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.
    Chun FK; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Stillebroer AB; van Gils MP; Schalken JA; Fradet Y; Marks LS; Ellis W; Partin AW; Haese A
    Eur Urol; 2009 Oct; 56(4):659-67. PubMed ID: 19304372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External validation of a PCA-3-based nomogram for predicting prostate cancer and high-grade cancer on initial prostate biopsy.
    Greene DJ; Elshafei A; Nyame YA; Kara O; Malkoc E; Gao T; Jones JS
    Prostate; 2016 Aug; 76(11):1019-23. PubMed ID: 27197726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are prostate biopsies necessary for all patients 75years and older?
    Chen Y; Fan Y; Yang Y; Jin J; Zhou L; He Z; Zhao Z; He Q; Wang X; Yu W; Wu S
    J Geriatr Oncol; 2018 Mar; 9(2):124-129. PubMed ID: 28939384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
    Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
    Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing the use of nomograms by choosing threshold points in predictive models: 2012 updated Partin Tables vs a European predictive nomogram for organ-confined disease in prostate cancer.
    Borque Á; Rubio-Briones J; Esteban LM; Sanz G; Domínguez-Escrig J; Ramírez-Backhaus M; Calatrava A; Solsona E
    BJU Int; 2014 Jun; 113(6):878-86. PubMed ID: 24529282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme.
    Rubio-Briones J; Casanova J; Martínez F; Domínguez-Escrig JL; Fernández-Serra A; Dumont R; Ramírez-Backhaus M; Gómez-Ferrer A; Collado A; Rubio L; Molina A; Vanaclocha M; Sala D; Lopez-Guerrero JA
    Actas Urol Esp; 2017 Jun; 41(5):300-308. PubMed ID: 28342633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer antigen-3 (PCA3) and PCA3-based nomograms in the diagnosis of prostate cancer: an external validation of Hansen's nomogram on a Norwegian cohort.
    Nygård Y; Haukaas SA; Eide GE; Halvorsen OJ; Gravdal K; Frugård J; Akslen LA; Beisland C
    Scand J Urol; 2015 Feb; 49(1):8-15. PubMed ID: 25141128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.
    Cao Y; Cao M; Chen Y; Yu W; Fan Y; Liu Q; Gao G; Zhao Z; Wang X; Jin J
    Oncotarget; 2017 Jul; 8(27):44040-44049. PubMed ID: 28476042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Nomogram Based on a TRUS Five-Grade Scoring System for the Prediction of Prostate Cancer and High Grade Prostate Cancer at Initial TRUS-Guided Biopsy.
    Xie SW; Wang YQ; Dong BJ; Xia JG; Li HL; Zhang SJ; Li FH; Xue W
    J Cancer; 2018; 9(23):4382-4390. PubMed ID: 30519343
    [No Abstract]   [Full Text] [Related]  

  • 13. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort.
    Salagierski M; Mulders P; Schalken JA
    Anticancer Res; 2013 Feb; 33(2):553-7. PubMed ID: 23393348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
    Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
    Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could Magnetic Resonance Imaging Help to Identify the Presence of Prostate Cancer Before Initial Biopsy? The Development of Nomogram Predicting the Outcomes of Prostate Biopsy in the Chinese Population.
    Fang D; Zhao C; Ren D; Yu W; Wang R; Wang H; Li X; Yin W; Yu X; Yang K; Liu P; Shan G; Li S; He Q; Wang X; Xin Z; Zhou L
    Ann Surg Oncol; 2016 Dec; 23(13):4284-4292. PubMed ID: 27464612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy.
    Ruffion A; Devonec M; Champetier D; Decaussin-Petrucci M; Rodriguez-Lafrasse C; Paparel P; Perrin P; Vlaeminck-Guillem V
    Int J Mol Sci; 2013 Aug; 14(9):17767-80. PubMed ID: 23994838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information.
    Zaytoun OM; Kattan MW; Moussa AS; Li J; Yu C; Jones JS
    Urology; 2011 Aug; 78(2):392-8. PubMed ID: 21705045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy.
    Perdonà S; Bruzzese D; Ferro M; Autorino R; Marino A; Mazzarella C; Perruolo G; Longo M; Spinelli R; Di Lorenzo G; Oliva A; De Sio M; Damiano R; Altieri V; Terracciano D
    Prostate; 2013 Feb; 73(3):227-35. PubMed ID: 22821756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy.
    Jeong IG; Lim JH; Hwang SS; Kim SC; You D; Hong JH; Ahn H; Kim CS
    Prostate Int; 2013; 1(2):69-75. PubMed ID: 24223405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nomogram conundrum: a demonstration of why a prostate cancer risk model in Turkish men underestimates prostate cancer risk in the USA.
    Kara O; Elshafei A; Nyame YA; Akdogan B; Malkoc E; Gao T; Altan M; Citamak B; Mammadov E; Dursun F; Greene DJ; Senkul T; Ates F; Ozen H; Stephen Jones J
    Int Urol Nephrol; 2016 Oct; 48(10):1623-9. PubMed ID: 27236298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.